DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+3.45%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.35B
AUM Growth
+$3.35B
(-3.7%)
Cap. Flow
-$548M
Cap. Flow
% of AUM
-16.37%
Top 10 Holdings %
Top 10 Hldgs %
41.71%
Holding
75
New
10
Increased
22
Reduced
20
Closed
8
Top Buys
| 1 |
Immunovant
IMVT
|
$63.1M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$57.5M |
| 3 |
TG Therapeutics
TGTX
|
$51.1M |
| 4 |
Axsome Therapeutics
AXSM
|
$44.1M |
| 5 |
argenx
ARGX
|
$43M |
Top Sells
| 1 |
AGEN
Agenus
AGEN
|
$526M |
| 2 |
Insmed
INSM
|
$187M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$80.8M |
| 4 |
Geron
GERN
|
$74.2M |
| 5 |
Apogee Therapeutics
APGE
|
$52.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Amgen
AMGN
$155B
| $180M | 5.36% | 575,000 +25,000 | +5% | +$7.81M |
|
|
2
argenx
ARGX
$43.6B
| $172M | 5.13% | 400,000 +100,000 | +33% | +$43M |
|
|
3
Axsome Therapeutics
AXSM
$6.05B
| $149M | 4.45% | 1,852,784 +548,063 | +42% | +$44.1M |
|
4
Dyne Therapeutics
DYN
$1.92B
| $141M | 4.21% | 4,000,000 -555,383 | -12% | -$19.6M |
|
|
SWTX
5
DELISTED
SpringWorks Therapeutics
SWTX
| $139M | 4.16% | 3,700,000 +220,147 | +6% | +$8.29M |
|
|
6
Insmed
INSM
$28.8B
| $134M | 4% | 2,000,000 -2,783,679 | -58% | -$187M |
|
7
Guardant Health
GH
$8.41B
| $130M | 3.88% | 4,500,000 -1,500,000 | -25% | -$43.3M |
|
8
Dynavax Technologies
DVAX
$1.19B
| $122M | 3.65% | 10,900,000 +1,758,340 | +19% | +$19.7M |
|
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $122M | 3.63% | 500,000 -332,310 | -40% | -$80.8M |
|
10
Intellia Therapeutics
NTLA
$1.22B
| $107M | 3.21% | 4,800,000 +589,216 | +14% | +$13.2M |
|
|
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $105M | 3.14% | 1,537,922 +37,922 | +3% | +$2.6M |
|
|
12
Apellis Pharmaceuticals
APLS
$3.48B
| $95.9M | 2.86% | 2,500,000 +1,500,000 | +150% | +$57.5M |
|
13
Ionis Pharmaceuticals
IONS
$6.8B
| $95.3M | 2.85% | 2,000,000 +626,525 | +46% | +$29.9M |
|
14
Ocular Therapeutix
OCUL
$2.12B
| $87M | 2.6% | 12,721,460 | – | – |
|
15
4D Molecular Therapeutics
FDMT
$288M
| $85.2M | 2.54% | 4,061,401 +1,026,948 | +34% | +$21.6M |
|
16
Alkermes
ALKS
$4.78B
| $84.4M | 2.52% | 3,500,000 | – | – |
|
17
Nurix Therapeutics
NRIX
$714M
| $83.3M | 2.49% | 3,991,500 +993,670 | +33% | +$20.7M |
|
|
18
Immunovant
IMVT
$2.56B
| $76.1M | 2.27% | 2,883,736 +2,390,384 | +485% | +$63.1M |
|
|
BCYC
19
Bicycle Therapeutics
BCYC
$511M
| $70.6M | 2.11% | 3,490,506 | – | – |
|
20
Pliant Therapeutics
PLRX
$101M
| $64.2M | 1.92% | 5,972,257 +222,257 | +4% | +$2.39M |
|
21
Travere Therapeutics
TVTX
$1.56B
| $60.6M | 1.81% | 7,370,000 | – | – |
|
|
VRNA
22
Verona Pharma
VRNA
$9.16B
| $57.8M | 1.73% | 4,000,000 +812,585 | +25% | +$11.7M |
|
|
ABVX
23
Abivax
ABVX
$6.12B
| $55.3M | 1.65% | 4,179,763 -117,675 | -3% | -$1.56M |
|
|
24
Geron
GERN
$893M
| $55.1M | 1.65% | 13,000,000 -17,505,929 | -57% | -$74.2M |
|
|
AUTL
25
Autolus Therapeutics
AUTL
$399M
| $53.1M | 1.59% | 15,272,172 | – | – |
|